exRNAdisease

Entry Detail

---



General Information

Database ID: exR0088161 RNA Name: hsa-miR-324-3p RNA Type: miRNA Chromosome: chr17 Starnd: - Coordinate: Start Site(bp): 7223308 End Site(bp): 7223330 External Links: hsa-miR-324-3p

Disease Information

Disease Name: Breast Cancer Disease Category: Cancers MeSH ID: D001943 Type: Neoplasms/Breast Neoplasms Alias: Breast Neoplasms//Breast Neoplasm//Neoplasm, Breast//Breast Tumors//Breast Tumor//Tumor, Breast//Tumors, Breast//Neoplasms, Breast//Breast Cancer//Cancer, Breast//Mammary Cancer//Cancer, Mammary//Cancers, Mammary//Mammary Cancers//Malignant Neoplasm of Breast//Breast Malignant Neoplasm//Breast Malignant Neoplasms//Malignant Tumor of Breast//Breast Malignant Tumor//Breast Malignant Tumors//Cancer of Breast//Cancer of the Breast//Mammary Carcinoma, Human//Carcinoma, Human Mammary//Carcinomas, Human Mammary//Human Mammary Carcinomas//Mammary Carcinomas, Human//Human Mammary Carcinoma//Mammary Neoplasms, Human//Human Mammary Neoplasm//Human Mammary Neoplasms//Neoplasm, Human Mammary//Neoplasms, Human Mammary//Mammary Neoplasm, Human//Breast Carcinoma//Breast Carcinomas//Carcinoma, Breast//Carcinomas, Breast

Expression Detail

GEO ID: GSE101841 Description: Serum microRNA profile of Her2 positive metastatic breast cancer patients Experimental Design: Trastuzumab therapy Case Disease Type: Breast Cancer Case Disease SubType: HER2 positive metastatic breast cancer Case Sample: Breast Cancer Trastuzumab resistant Control Sample: Trastuzumab sensitive Number of Case: 42 Number of Control: 61 Number of Samples: 103

Regulatory Relationship

mRNA targets: Gene Symbol Chromosome Start Site(bp) End Site(bp) Strand ACLY chr17 41866917 41930542 - ATXN7L3 chr17 44191805 44200113 - CDC42EP2 chr11 65314866 65322417 + CELSR2 chr1 109249539 109275751 + DBNDD1 chr16 90004871 90020128 - DCAF15 chr19 13952492 13961449 + FBXL19 chr16 30923055 30948783 + LNPEP chr5 96935394 97037513 + MAPKAPK2 chr1 206684944 206734283 + MXD4 chr4 2247432 2262109 - NACC1 chr19 13116862 13141147 + PDRG1 chr20 31944337 31952046 - SMAD7 chr18 48919853 48952052 - SPTBN2 chr11 66685248 66729226 - SYVN1 chr11 65121780 65134533 - TAGLN chr11 117199370 117207464 + TNFRSF10B chr8 23020133 23069031 - TULP4 chr6 158232236 158511828 + miRNA targets: NA circRNA targets: circRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand hsa_circ_0001727 chr7 99621041 99621930 + lncRNA targets: lncRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand AC040162.3 chr16 67882461 67886367 + AC234582.1 chr1 155195004 155205495 + KCNQ1OT1 chr11 2608328 2699994 - LINC01521 chr22 31346777 31348719 + MALAT1 chr11 65497688 65506516 + NEAT1 chr11 65422774 65445540 + NORAD chr20 36045618 36051018 - SNHG22 chr18 49814023 49851059 + Display:

Experiment Detail

GEO ID: GSE101841 Sample Source: Blood Source Fraction: Serum Platform: GPL23138 Method: Microarray Num of detected RNA Type: 1 Num of detected RNAs of this Type: 1808 Sample treatment protocol: NA RNA Extract protocol: Total RNA was extracted from 103 samples with the Plasma RNA Purification Mini Kit (51000, NorgenBiotek Corporation, Canada), following manufacturer's instructions. RNA library preparation protocol: Total RNA extracted from 600ul serum was employed with 100 nmol/L of pCp-DY647 and 15 Units of T4 RNA ligase in a total reaction volume of 20 ul at 16°C overnight.

Reference

PMID: 29691399 Title: A serum microRNA signature predicts trastuzumab benefit in HER2-positive metastatic breast cancer patients. Author: Li H, Liu J, Chen J, Wang H, Yang L, Chen F, Fan S, Wang J, Shao B, Yin D, Zeng M, Li M, Li J, Su F, Liu Q, Yao H, Su S, Song E Journal: Nat Commun. 2018 Apr 24;9(1):1614. Description: MicroRNAs (miRNAs) have been used to predict therapeutic effects for various cancers, but whether miRNAs can serve as biomarkers for HER2+ metastatic breast cancer (MBC) patients remains unclear.